Affordable Access

Access to the full text

Melatonin for rapid eye movement sleep behavior disorder in Parkinson's disease : a randomised controlled trial

  • Gilat, Moran
  • Coeytaux Jackson, Alessandra
  • Marshall, Nathaniel S.
  • Hammond, Deborah
  • Mullins, Anna E.
  • Hall, Julie
  • Fang, Bernard A.M.
  • Yee, Brendon J.
  • Wong, Keith K.H.
  • Grunstein, Ron R.
  • Lewis, Simon J. G.
Publication Date
Jan 01, 2020
DOI: 10.1002/mds.27886
Ghent University Institutional Archive
External links


Background Melatonin may reduce REM-sleep behavior disorder (RBD) symptoms in Parkinson's disease (PD), though robust clinical trials are lacking. Objective To assess the efficacy of prolonged-release (PR) melatonin for RBD in PD. Methods Randomized, double-blind, placebo-controlled, parallel-group trial with an 8-week intervention and 4-week observation pre- and postintervention (ACTRN12613000648729). Thirty PD patients with rapid eye movement sleep behavior disorder were randomized to 4 mg of prolonged-release melatonin (Circadin) or matched placebo, ingested orally once-daily before bedtime. Primary outcome was the aggregate of rapid eye movement sleep behavior disorder incidents averaged over weeks 5 to 8 of treatment captured by a weekly diary. Data were included in a mixed-model analysis of variance (n = 15 per group). Results No differences between groups at the primary endpoint (3.4 events/week melatonin vs. 3.6 placebo; difference, 0.2; 95% confidence interval = -3.2 to 3.6; P = 0.92). Adverse events included mild headaches, fatigue, and morning sleepiness (n = 4 melatonin; n = 5 placebo). Conclusion Prolonged-release melatonin 4 mg did not reduce rapid eye movement sleep behavior disorder in PD. (c) 2019 The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society.

Report this publication


Seen <100 times